The platform has also been proven through $20 million of partnerships with Dow, DSM, Unilever, NatureWorks/Cargill, Kyowa Hakko, and Verenium; and over 30 peer-reviewed projects funded by the National Institutes of Health, National Science Foundation, Department of Energy, Department of Defense and Environmental Protection Agency.
Significance to the Industry
"Genomatica's platform technology is the greatest enabling technology I've seen for industrial biotechnology – and I've seen a lot," said Bernhard Hauer, formerly BASF's vice president, research, and now professor at the University of Stuttgart. "This has the potential to catalyze a transformation of the chemical industry – no pun intended."
"The speed with which Genomatica introduced new generations of its 1,4-butanediol organism is impressive," said David Jones, Senior Vice President of MBI. "The company has set a new standard."
"By successfully implementing the manufacturing process at this scale, we have shown that our first product is ready for commercialization and that our platform delivers," said Mark Burk, chief technology officer of Genomatica. "Our bio-based BDO process will be cost-advantaged when compared to existing methods. We're looking forward to delivering these same advantages to additional products and processes."
Genomatica is the emerging le
Copyright©2010 PR Newswire.
All rights reserved